



(11) **EP 2 127 675 A1**

(12) **EUROPEAN PATENT APPLICATION**  
published in accordance with Art. 153(4) EPC

(43) Date of publication:  
**02.12.2009 Bulletin 2009/49**

(21) Application number: **08720540.7**

(22) Date of filing: **19.03.2008**

(51) Int Cl.:  
**A61K 45/06** <sup>(2006.01)</sup> **A61K 31/122** <sup>(2006.01)</sup>  
**A61K 31/7105** <sup>(2006.01)</sup> **A61K 48/00** <sup>(2006.01)</sup>  
**A61P 31/12** <sup>(2006.01)</sup> **A61P 31/16** <sup>(2006.01)</sup>  
**A61P 43/00** <sup>(2006.01)</sup>

(86) International application number:  
**PCT/JP2008/000655**

(87) International publication number:  
**WO 2008/117523 (02.10.2008 Gazette 2008/40)**

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT  
RO SE SI SK TR**

(30) Priority: **23.03.2007 JP 2007077970**

(71) Applicants:  
• **Nippon Soda Co., Ltd.**  
**Tokyo 100-8165 (JP)**  
• **HOKKAIDO UNIVERSITY**  
**Hokkaido 060-0808 (JP)**

(72) Inventors:  
• **SANO, Shinsuke**  
**Odawara-shi**  
**Kanagawa 250-0280 (JP)**

• **FUKAGAWA, Takako**  
**Odawara-shi**  
**Kanagawa 250-0280 (JP)**  
• **YAMADA, Hirokazu**  
**Odawara-shi**  
**Kanagawa 250-0280 (JP)**  
• **MASUTA, Chikara**  
**Sapporo-shi**  
**Hokkaido 060-8589 (JP)**  
• **SHIMURA, Hanako**  
**Sapporo-shi**  
**Hokkaido 060-8589 (JP)**

(74) Representative: **Wibbelmann, Jobst et al**  
**Wuesthoff & Wuesthoff**  
**Patent- und Rechtsanwälte**  
**Schweigerstrasse 2**  
**81541 München (DE)**

(54) **ANTIVIRAL AGENT**

(57) An object of the present invention is to provide a viral disease control agent which has a mechanism of action different from conventional one as a substitute for existing viral disease control methods and is used in more practical and safer manners. The present invention utilizes a compound having inhibitory activity on the binding

of a substance  $\alpha$  to a PTGS suppressor protein, wherein the substance  $\alpha$  has a property of inducing PTGS and a property of binding to the PTGS suppressor protein and shows a decrease in the property of inducing PTGS upon binding to the PTGS suppressor protein.

**EP 2 127 675 A1**

**Description****Technical Field**

5 **[0001]** The present invention relates to a PTGS suppressor protein binding inhibitor and an antiviral agent having a novel mechanism of action.

**Background Art**

10 **[0002]** A very large number of pathogenic viruses have spread on earth, and their infection has caused suffering or economic losses in various organisms such as animals including humans and useful plants (e.g., crops). Examples of viral diseases caused by a pathogenic virus infection include rice dwarf disease caused by rice dwarf virus infection, tomato mosaic disease caused by tobacco mosaic virus infection, human influenza caused by influenza virus infection, human hepatitis B caused by hepatitis B virus infection, and acquired immune deficiency syndrome caused by human immunodeficiency virus (HIV) infection.

15 **[0003]** Host organisms such as plants or animals, when infected with pathogenic viruses, develop various biological defense mechanisms against the infection to inhibit the growth of the viruses or to relieve the disease symptom. One of these defense mechanisms is post-transcriptional gene silencing (hereinafter, abbreviated to PTGS). PTGS is a phenomenon induced by double-stranded RNAs (dsRNAs) of viruses or the like, wherein transcribed messenger RNAs (mRNAs) are degraded in a sequence-specific manner. PTGS is a mechanism conserved not only in higher organisms such as plants or animals but also in various other organism species from protozoans to fungi and is thought to be a particularly important defense mechanism for plants which do not have an immune system, unlike animals. Specifically, in this mechanism, PTGS-inducing dsRNAs are degraded by intracellular nuclease Dicer or an enzyme analogous thereto into short RNAs of approximately 21 to 24 bases called small interfering RNAs (siRNAs), and the siRNA is further incorporated into a nuclease complex called an RNA-induced silencing complex (RISC), which in turn cleaves mRNA homologous to the siRNA sequence, thereby inhibiting the expression of the target protein such as viruses.

20 **[0004]** It has recently been revealed that many pathogenic viruses encode, as a counter against the PTGS mechanism of host organisms, a suppressor protein that inhibits this PTGS (PTGS suppressor protein; hereinafter, abbreviated to PTGS-SP) (e.g., Patent Document 1). It has further been reported that the majority of these PTGS-SPs inhibit PTGS through the direct binding to siRNAs (e.g., Non-Patent Document 1).

25 **[0005]** PTGS-SPs expressed by plant viruses have been reported, for example, HC-Pro of viruses of the genus *Potyvirus* (see Non-Patent Document 2), 2b of viruses of the genus *Cucumovirus* (see Non-Patent Document 3), p25 of viruses of the genus *Potexvirus* (see Non-Patent Document 4), p19 of viruses of the genus *Tombusvirus* (see Non-Patent Document 5), and coat proteins of viruses of the genus *Carmovirus* (see Non-Patent Document 6).

30 **[0006]** Many attempts have been made to develop preventive or therapeutic agents for the viral diseases for reducing damages caused by the viral diseases. For example, M2 ion-channel inhibitors (e.g., amantadine) and neuraminidase inhibitors (e.g., zanamivir phosphate and oseltamivir) are known as effective therapeutic agents for influenza. These M2 ion-channel and neuraminidase inhibitors probably exert therapeutic effects on influenza by preventing the influenza viruses from growing or infecting other cells. Moreover, known effective therapeutic agents for acquired immune deficiency syndrome are broadly classified into reverse transcriptase inhibitors (e.g., azidothymidine and didanosine) and protease inhibitors (e.g., ritonavir and indinavir). Multi-drug therapy using these agents exerts remarkable effects, which drastically reduces the number of deaths in advanced countries.

35 **[0007]** However, these therapeutic agents for influenza or acquired immune deficiency syndrome are also known to have side effects, and it is believed that drug resistance viruses will inevitably appear due to the variability of the viruses. Therefore, the development of a novel antiviral agent having a different mechanism of action has been demanded. Furthermore, agents against viruses, except for some agents structurally similar to nucleic acids, are only applicable to a target viral disease. Moreover, vaccination, albeit effective, must be performed before infection and has problems such as time taken to develop antibodies or the easily variable antigenic site of viruses. Furthermore, the therapeutic agents or vaccines are only applicable to a target viral disease. Therefore, therapeutic agents for viral diseases had to be developed for each type of virus.

40 **[0008]** On the other hand, various control methods have been developed for viral diseases in plants. Examples thereof include selective breeding of resistant varieties to viral diseases, raising of virus-free plants by stem tip culture or heat treatment, inhibition of pathogenic virus infection by treatment with selected attenuated viruses, and use of plants having virus resistance imparted by transformation. Moreover, examples of the control methods using agricultural chemicals include use of a fungicide that induces the resistance of plants or an insecticide that targets insect vectors or the like for viruses.

45 **[0009]** However, the breeding of resistant varieties requires a long period, and resistant strains of viruses inevitably appear. The raising of virus-free plants by stem tip culture or the like is not perfect. The use of attenuated viruses is

highly effective for viral disease control. However, attenuated viruses are difficult to stably prepare and are effective only for viruses of the same species or related species. Plant defense activators have unstable effects. Spraying large amounts of insecticide that preventively controls insect vectors for viruses may lead to environmental pollution and cannot be expected to have therapeutic effects on virus-infected plants.

**[0010]** On the other hand, urgency and markets for antiviral agents for viral diseases in plants are much smaller than those for antiviral agents for viral diseases in humans. Therefore, it is highly possible that the cost of developing the antiviral agents for viral diseases in plants cannot be recovered even if they are developed at cost much lower than the cost of developing the antiviral agents for viral diseases in humans, for example, anti-HIV drugs or anti-influenza drugs. In addition, the existing vaccines or antiviral agents are expected, as described above, to be effective only for the target viruses, and resistant strains of viruses inevitably appear. Therefore, the development of antiviral agents for viral diseases in plants has hardly proceeded so far.

**[0011]**

Patent Document 1: Japanese Laid-Open Patent Application No. 2004-344110

Non-Patent Document 1: Goto K., et al., Plant Cell Physiol. 2007, 48, 1050-60

Non-Patent Document 2: Anandalakshmi R., et al., Proc. Natl. Acad. Sci. USA, 1998, 95, 13079-13084

Non-Patent Document 3: Brigneti G., et al., EMBO J., 1998, 17, 6739-6746

Non-Patent Document 4: Voinnet O., et al., Cell, 2000, 103, 157-167

Non-Patent Document 5: Baulcombe DC., et al., Trends Biochem Sci. 2004, 29, 279-81

Non-Patent Document 6: Qu F., et al., J. Virol. 2003, 77, 511-522

## Disclosure of the Invention

### Object to be Solved by the Invention

**[0012]** It has been demanded to provide a control method which has a mechanism of action different from conventional one as a substitute for the existing viral disease control methods described above and is used in more practical and safer manners. Thus, an object of the present invention is to provide a viral disease control agent having a mechanism of action different from conventional one.

### Means to Solve the Object


**[0013]** The present inventors have conducted diligent studies in consideration of the object and consequently found that a therapeutic effect of reducing damages caused by viral diseases or an effect of attenuating highly virulent viruses having strong pathogenicity is obtained without toxicity to or strong influence on applicable organisms by inhibiting the binding of PTGS-SP to siRNA such that the PTGS-SP function is inhibited. Furthermore, the present inventors have actually studied the effects of compounds that actually inhibit the functions of various PTGS-SPs. Based on these findings, the present invention has been completed.

**[0014]** Specifically, the present invention relates to:


[1] a PTGS suppressor protein binding inhibitor containing a compound having inhibitory activity on the binding of a substance  $\alpha$  to a PTGS suppressor protein, wherein the substance  $\alpha$  has a property of inducing PTGS and a property of binding to the PTGS suppressor protein and shows a decrease in the property of inducing PTGS upon binding to the PTGS suppressor protein;

[2] the PTGS suppressor protein binding inhibitor according to [1], wherein the substance  $\alpha$  is siRNA; and


[3] the PTGS suppressor protein binding inhibitor according to [1] or [2], wherein the compound is at least one selected from the group consisting of cyclic ketone compounds represented by the following formulas (1) to (6):




.... Formula (1)




.... Formula (2)




.... Formula (3)



.... Formula (4)



.... Formula (5)



.... Formula (6)


**[0015]** Moreover, the present invention relates to:

[4] the PTGS suppressor protein binding inhibitor according to [1] or [2], wherein the compound is a reaction product of croconic acid with hydrogen peroxide;


[5] an antiviral agent comprising as an active ingredient a compound having inhibitory activity on the binding of a substance  $\alpha$  to a PTGS suppressor protein, wherein the substance  $\alpha$  has a property of inducing PTGS and a property of binding to the PTGS suppressor protein and shows a decrease in the property of inducing PTGS upon binding to the PTGS suppressor protein;

[6] the antiviral agent according to [5], wherein the substance  $\alpha$  is siRNA; and


[7] the antiviral agent according to [5] or [6], wherein the compound is at least one selected from the group consisting of cyclic ketone compounds represented by the following formulas (1) to (6):




..... Formula (1)




..... Formula (2)




..... Formula (3)



..... Formula (4)



Formula (5)



Formula (6)

**[0016]** Furthermore, the present invention relates to; [8] the antiviral agent according to [5] or [6], wherein the compound is a reaction product of croconic acid with hydrogen peroxide.

#### Brief Description of Drawings

**[0017]**

[Figure 1] It is a graph showing the inhibitory activity of compound 7 of the present invention on CMV 2b according to a protoplast method.

[Figure 2] It is a photograph showing the inhibitory activity of compound 7 of the present invention on CMV 2b according to a silencing plant method.

[Figure 3] It is a graph showing the antiviral activity of compound 7 of the present invention according to a symptom test method.

#### Best Mode of Carrying Out the Invention

**[0018]** A PTGS-SP binding inhibitor of the present invention is characterized by containing a compound having inhibitory activity on the binding of PTGS-SP to a substance  $\alpha$  (hereinafter, also referred to as a "compound according to the present invention"), wherein the substance  $\alpha$  has a property of inducing PTGS and a property of binding to the PTGS-SP and shows a decrease in the property of inducing PTGS upon binding to the PTGS-SP. The inhibition of the binding of a substance  $\alpha$  to PTGS-SP can restore the substance  $\alpha$  function inhibited by PTGS-SP, i.e., the function of inducing PTGS. Therefore, the use of the compound according to the present invention can reduce the inhibitory effect of viruses on PTGS, resulting in, for example, the reduced toxicity or inhibited growth of the viruses. As a result, an antiviral effect is obtained.

(PTGS-SP protein)

**[0019]** The PTGS-SP targeted by the PTGS-SP binding inhibitor according to the present invention is not particularly limited as long as it is a protein that is derived from any kind of virus and has the ability to inhibit the PTGS of one or more organisms. Preferable examples of the organisms can include plants and animals. The plants can be exemplified more preferably by: food crops such as cereals (e.g., rice, wheat, and corn), pulse crops (e.g., soybean and peanut), tubers (e.g., potato and sweet potato), vegetables (e.g., Japanese radish, carrot, cabbage, lettuce, eggplant, cucumber, and tomato), and fruit trees (e.g., apple, pear, and citrus); and nonfood crops such as flowers and ornamental plants (e.g., rose, carnation, and chrysanthemum), foliage plants (e.g., ivy and maidenhair), and trees (e.g., pine and cherry). More preferable examples of the animals can include birds and mammals such as human, monkey, chimpanzee, cow, horse, pig, sheep, rabbit, dog, cat, rat, mouse, and guinea pig.

**[0020]** Specifically, the PTGS-SP targeted by the PTGS-SP binding inhibitor according to the present invention can be exemplified preferably by: PTGS-SPs derived from viruses whose natural host is a plant, such as HC-Pro of viruses of the genus *Potyvirus* (e.g., TuMV: turnip mosaic virus), 2b of viruses of the genus *Cucumovirus* (e.g., CMV: cucumber

mosaic virus), p25 of viruses of the genus *Potexvirus* (e.g., PVX: potato virus X), p19 of viruses of the genus *Tombusvirus* (e.g., TBSV: tomato bushy stunt virus), and coat proteins of viruses of the genus *Carmovirus* (e.g., CarMV: carnation mottle virus); and PTGS-SPs derived from viruses whose natural host is an animal (particularly, a mammal), such as tat (Genbank Accession No. NC\_001802 or NC\_001722) of viruses of the genus *Lentivirus* (e.g., HIV: human immunodeficiency virus), NS1 (Genbank Accession No. NC\_002020) of viruses of the genus *Influenzavirus A* (e.g., FLUAV: influenza A virus), NS1 (Genbank Accession No. NC\_002211) of viruses of the genus *Influenzavirus B* (e.g., FLUBV: influenza B virus), and NS1 of viruses of the genus *Influenzavirus C* (e.g., FLUCV: influenza C virus).

**[0021]** In addition to the above-exemplified PTGS-SPs known in the art, any protein that functions as PTGS-SP can be targeted by the PTGS-SP binding inhibitor of the present invention.

Whether a certain protein is a PTGS-SP can be confirmed by: for example, artificially inducing PTGS of an arbitrary gene in a cell; causing the cell to express the protein simultaneously with a protein encoded by the arbitrary gene; and examining the recovery of the arbitrary gene from PTGS, compared with the cell not expressing the protein. The decrease in PTGS can be confirmed by detecting a decrease in the accumulation level of mRNAs of the gene targeted by PTGS or a decrease in the accumulation level of its target protein itself.

For example, whether a certain protein is a PTGS-SP can be confirmed by an agroinfiltration method which involves: injecting a GFP (green fluorescence protein) gene into the intercellular space of a plant leaf using *Agrobacterium*; and transiently inducing PTGS of the GFP gene. A virus gene encoding a PTGS-SP candidate is expressed simultaneously with the GFP gene, and the protein encoded by this virus gene is identified as PTGS-SP when light emitted by GFP is observed. Alternatively, it can also be confirmed by a protoplast method which involves transiently inducing PTGS of the GFP gene using the protoplast of a plant leaf. In this case, the GFP gene and so on are directly incorporated into the protoplast by polyethylene glycol (PEG), and PTGS-SP can be identified based on the presence or absence of light emitted by GFP.

(Substance  $\alpha$ )

**[0022]** The substance  $\alpha$  according to the present invention is not particularly limited as long as it is a substance that has property of binding to any PTGS-SP and property of inducing PTGS in the cell of any organism and shows a decrease in its own property of inducing PTGS upon binding to the PTGS-SP. The substance  $\alpha$  is preferably a nucleic acid, more preferably virus-derived RNA (e.g., dsRNA or siRNA), and even more preferably siRNA. Specifically, the RNA used as the substance  $\alpha$  can be exemplified by a virus-derived RNA sequence or a portion thereof and can be exemplified more preferably by virus-derived siRNA of 21 to 23 bases.

**[0023]** The sequence of the dsRNA or siRNA used as the substance  $\alpha$  according to the present invention is not particularly limited and is preferably a sequence (or a partial sequence thereof) corresponding to the nucleic acid of a virus serving as a target to obtain the antiviral effect or an RNA sequence transcribed from the nucleic acid, more preferably a sequence of 20 to 27 bases corresponding to the nucleic acid of a virus serving as a target to obtain the antiviral effect or an RNA sequence transcribed from the nucleic acid, and even more preferably a sequence of 21 to 23 bases corresponding to the nucleic acid of a virus serving as a target to obtain the antiviral effect or an RNA sequence transcribed from the nucleic acid.










Whether the substance  $\alpha$  such as dsRNA or siRNA binds to PTGS-SP can be confirmed by using a method described later such as surface plasmon resonance, single-molecule fluorescence analysis, gel shift assay, and thermal denaturation. Moreover, whether the substance  $\alpha$  such as dsRNA or siRNA shows a decrease in its property of inducing PTGS upon binding to the PTGS-SP can be confirmed by: artificially inducing PTGS of an arbitrary gene in a cell; causing the cell to express PTGS-SP; and examining the promotion of the intracellular PTGS in the presence of the particular substance, compared with the absence of the substance.

(Inhibitor of the present invention)

**[0024]** The compound used as the inhibitor according to the present invention is not particularly limited as long as it has inhibitory activity on the binding of a substance  $\alpha$  to PTGS-SP. The compound according to the present invention also includes compounds such as proteins (e.g., antibodies) and nucleic acids. Specifically, the compound according to the present invention can be exemplified preferably by compounds shown in Table 1 below or derivatives thereof. These compounds are cyclic ketone compounds. The compounds of compound Nos. 7 and 8 are reaction products of croconic acid with hydrogen peroxide, synthesized in Synthesis Examples 1 and 2, respectively. The compound according to the present invention other than the compounds shown in Table 1 can be identified easily by screening using an evaluation system of the present invention (in vitro and in vivo screening methods) described later.

**[0025]**










[Table 1]

Compound No.	Structural formula
1	
2	
3	
4	
5	
6	
7	Compound of Synthesis Example 1
8	Compound of Synthesis Example 2
9	
10	
11	



# EP 2 127 675 A1

(continued)

Compound No.	Structural formula
12	
13	
14	
15	
16	
17	
18	
19	
20	

Of these compounds, the compounds of compound Nos. 5, 6, 7, 8, 12, 13, 14, and 20 are preferred.

**[0026]** Of the compounds of above Table 1, compound Nos. 7 and 8 are novel compounds, and the compounds other than compound Nos. 7 and 8 are commercially available.

**[0027]** These compounds or derivatives thereof can be synthesized by performing a reaction known in the art with appropriate compounds as raw material compounds. Particularly, the above compound Nos. 7 and 8 can be synthesized

by, for example, methods specifically described later in Examples.

The PTGS-SP binding inhibitor of the present invention may contain only one of the compounds according to the present invention or may contain two or more thereof.

(Antiviral agent of the present invention)

**[0028]** An antiviral agent of the present invention is characterized by comprising the compound of the present invention as an active ingredient. The use of the antiviral agent of the present invention can restore the substance  $\alpha$  function inhibited by PTGS-SP, i.e., the function of inducing PTGS. Based on such a mechanism of action, the antiviral agent of the present invention can reduce the inhibition of PTGS caused by highly virulent viruses, resulting in, for example, the inhibited growth or reduced toxicity of the viruses. As a result, the antiviral agent of the present invention exerts an antiviral effect.

**[0029]** The antiviral agent of the present invention may contain only one of the compounds according to the present invention as an active ingredient or may contain two or more thereof as active ingredients. Moreover, it is preferred from the viewpoint of obtaining a more excellent antiviral agent that the antiviral agent of the present invention should further contain a substance that promotes the general resistance of organisms to viruses unless the PTGS-SP binding inhibitory activity of the compound according to the present invention is inhibited. The substance that promotes the resistance of host organisms to viruses is not particularly limited and can be exemplified preferably by substances that promote the resistance of plants to viruses, such as fungicides known as plant defense activators (e.g., probenazole and tiadinil), or isonicotinic acid, salicylic acid, and ascorbic acid).

**[0030]** The antiviral agent of the present invention may contain optional additional ingredients unless the PTGS-SP binding inhibitory activity of the compound according to the present invention is inhibited. The optional additional ingredients can be exemplified by diluents or excipients such as fillers, expanders, binders, wetting agents, disintegrants, surfactants, and lubricants.

**[0031]** The dosage form of the PTGS-SP binding inhibitor or the antiviral agent of the present invention is not particularly limited and can be selected appropriately from tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules, suppositories, injections (solutions, suspensions, etc.), ointments, inhalants, sprays, and so on according to an applicable organism used. The amount of the PTGS-SP binding inhibitor or the antiviral agent used differs depending on the mode of use, an applicable organism used, the type of the compound of the present invention contained therein, and so on and can however be determined appropriately by those skilled in the art.

**[0032]** A method for using the PTGS-SP binding inhibitor or the antiviral agent of the present invention is not particularly limited and can be determined appropriately by those skilled in the art according to the property of the compound of the present invention contained therein, the type of an applicable organism used, and so on. When the applicable organism used is an animal, the use method can be exemplified preferably by oral administration, intravenous injection, intramuscular injection, transvaginal administration, transdermal application, and inhalation. When the applicable organism used is a plant, the use method can be exemplified preferably by foliage application, dip treatment, injection into soil, seed disinfection, and smoking.

**[0033]** The amount of the PTGS-SP binding inhibitor or the antiviral agent of the present invention used is not particularly limited and can be determined appropriately by those skilled in the art according to the type of an applicable organism used, a use method, and so on. Particularly, when the applicable organism used is an animal, the amount can be selected appropriately according to the age, body weight, and condition of the applicable organism used, an administration method, and so on.

(Screening method)

1) *in vitro* screening method

**[0034]** An *in vitro* screening method for the compound according to the present invention is not particularly limited as long as it is an evaluation method using the degree of inhibition of the binding of a substance  $\alpha$  to PTGS-SP as an index or an evaluation method which involves measuring the specific binding to PTGS-SP. Whether or not a test compound inhibits the binding of a substance  $\alpha$  to PTGS-SP or the degree of inhibition of the binding can be measured quantitatively and evaluated by using, for example, a known method such as single-molecule fluorescence analysis, surface plasmon resonance, gel shift assay, dual polarization interferometry, photothermal spectroscopy, and quartz crystal microbalance. The single-molecule fluorescence analysis method eliminates the need of sample immobilization and achieves multi-sample treatment under conditions of a solution system close to an *in vivo* environment. However, this method has the disadvantage that it is susceptible to interference of the autofluorescence of a compound. The surface plasmon resonance method requires sample immobilization and is however not influenced by the autofluorescence of a compound. The gel shift assay method is unsuitable for multi-sample treatment and however has the advantage that it eliminates the need

of sample immobilization and is not influenced by the autofluorescence of a compound.

**[0035]** The single-molecule fluorescence analysis method is an approach which involves: detecting a change in the behavior of labeled fluorescent molecules by measuring the number, intensity, or the like of the labeled fluorescent molecules using a confocal laser scanning microscope; and analyzing the intermolecular interaction between two substances. Screening based on the single-molecule fluorescence analysis method can be performed, for example, by applying a sample solution comprising PTGS-SP, a fluorescently labeled substance  $\alpha$ , and a test compound to a measurement apparatus for single-molecule fluorescence analysis such as Olympus MF20 to detect a change in the behavior of the labeled substance  $\alpha$ .

**[0036]** The surface plasmon resonance method is an apparatus which involves: monitoring a change in refractive index caused by, for example, a change in the weight of molecules immobilized on a thin gold film; and analyzing the intermolecular interaction between two substances. Screening based on the surface plasmon resonance method can be performed, for example, by: immobilizing a substance  $\alpha$  onto sensor chip surface; and applying a sample solution comprising PTGS-SP and a test compound to a Biacore measurement apparatus or the like to detect, as a change in the refractive index of the solution, a change in the weight of molecules caused by the binding of the substance  $\alpha$  immobilized on the sensor chip to the PTGS-SP.

**[0037]** The gel shift assay method is an approach which involves: mixing two high molecular substances; subjecting the mixture to electrophoresis; and analyzing whether the two substances are bound with each other, from the electrophoretic band positions or concentrations. Screening based on the gel shift assay can be performed, for example, by subjecting a sample solution comprising a labeled substance  $\alpha$ , PTGS-SP, and a test compound to polyacrylamide gel electrophoresis using a universal apparatus. The binding of the substance  $\alpha$  to the PTGS-SP increases a molecular weight, resulting in slow migration. By contrast, when the binding of the substance  $\alpha$  to the PTGS-SP is inhibited by the compound, the migration of the substance  $\alpha$  is faster. Therefore, the degree of the binding can be analyzed by comparing these electrophoretic band positions or amounts.

## 2) *in vivo* screening method

**[0038]** An *in vivo* screening method for the compound according to the present invention is not particularly limited as long as it is an evaluation method using the degree of inhibition of the PTGS-SP function as an index. Whether or not a test compound inhibits the PTGS-SP function can be evaluated by, for example, an agroinfiltration method, a protoplast method, a silencing plant method using a change in flower color as an index, or a symptom test method which involves examining the symptom of a viral disease using plant seedlings.

**[0039]** The agroinfiltration method is a method which involves: simultaneously injecting, for example, a GFP gene and a viral PTGS-SP gene into the intercellular space of a plant leaf using *Agrobacterium* for transient transformation; and conducting evaluation based on the principle that the GFP fluorescence disappears when PTGS functions while the GFP fluorescence is observed when the viral PTGS-SP functions. Furthermore, by treating the plant leaf with a test compound before and after the gene injection, the test compound can be determined to inhibit the PTGS-SP function when the GFP fluorescence disappears.

**[0040]** The protoplast method is a method based on the same principle as that of the agroinfiltration method. Specifically, this method utilizes protoplast instead of the plant leaf and involves: directly incorporating a firefly luciferase gene and a viral PTGS-SP gene into the protoplast by use of polyethylene glycol; and conducting evaluation based on the principle that light emission derived from the luciferase activity disappears when PTGS functions while stronger light emission is observed when the viral PTGS-SP functions. By treating the protoplast with a test compound, the test compound can be determined to inhibit the PTGS-SP function when light emission derived from the luciferase activity is significantly decreased, compared with untreated protoplast.

**[0041]** The silencing plant method is a method which utilizes the principle that a variety whose flower color is wholly or partially white shows a change in the flower color when infected with a plant virus having PTGS-SP. Specifically, this method utilizes the fact that the expression of pigment genes is inhibited by natural PTGS in many white flowers. The inhibition of pigment expression by PTGS is canceled by the virus infection such that the pigment gene is expressed. As a result, the flower exhibits a red or blue color changed from the white color. Here, the flower is treated with a compound, and the inhibitory effect of the compound can be determined based on a white flower color recovered by the inhibition of the viral PTGS-SP function.

**[0042]** The symptom test method using plant seedlings is a method which involves observing the symptom of a viral disease to determine the antiviral effect of a compound. Specifically, in this method, the plant seedlings are treated with a compound before and after inoculation of a plant virus whose infection causes a severe symptom in the plants, and the antiviral effect is determined based on the severity of the symptom.

## 3) Methods for preparing PTGS-SP and substance $\alpha$ for screening

**[0043]** The PTGS-SP targeted by the PTGS-SP binding inhibitor according to the present invention can be obtained using a universal approach, for example, PCR based on sequence information of the GenBank Accession No. described

above.

The PTGS-SP can be expressed in, for example, an expression system using *E. coli*, yeast, or insect cells or a cell-free protein synthesis system derived from wheat germs or rabbit reticulocytes.

When *E. coli* is used, a tag sequence is added to a sequence encoding the PTGS-SP of interest, and the sequence is inserted into an arbitrary vector for *E. coli* expression, with which an arbitrary *E. coli* strain can then be transformed to express the PTGS-SP. Then, it is preferred that the PTGS-SP is purified according to a standard method based on the type of the added tag. The PTGS-SP can be purified easily by adding, for example, His-tag for TBSV p19; or MBP (maltose-binding protein) for TAV (tomato aspermy virus) 2b (TAV 2b) or HIV tat, and can be used without troubles in the evaluation system.

**[0044]** In the present invention, instead of the PTGS-SP, a synthetic peptide having a partial structure thereof can also be used in the evaluation system. The synthetic peptide can be obtained as a peptide of 20 to 40 bases comprising the portion of two or more primarily consecutive or adjacent strongly basic amino acids (arginines or lysines) using a usual approach, for example, solid-phase synthesis using an Fmoc or Boc method based on the sequence information of the PTGS-SP.

**[0045]** In the present invention, instead of the PTGS-SP, even a length or sequence variant of a synthetic peptide having a partial structure thereof can also be used in the evaluation system of siRNA binding inhibition. The variant peptide used in the siRNA binding test must have a sequence of three or more primarily consecutive or adjacent strongly basic amino acids (arginines or lysines). For example, for HIV tat, consecutive arginines or lysines starting at N-terminal position 49 are important, and its ability to bind to siRNA is decreased by converting even one of arginines 52, 53, and 55 to a neutral amino acid leucine and the ability is lost by converting two or more thereof to leucine. The ability to bind to siRNA is maintained even if all of these arginines are converted to another strongly basic amino acid lysine. On the other hand, the ability to bind to siRNA is maintained even if independently located arginine such as arginine 78 is converted to a neutral amino acid leucine.

Moreover, the nucleic acid as the substance  $\alpha$ , such as dsRNA or siRNA, can be obtained using a universal approach, for example, PCR.

#### Examples

**[0046]** Hereinafter, the present invention will be described more specifically with reference to Examples. However, the technical scope of the present invention is not intended to be limited to these Examples.

#### (Synthesis of compound)

##### **[0047]** Synthesis Example 1 (Preparation of compound 7)

3.0 g of croconic acid was dissolved in 30 ml of pure water. To the solution, 1.2 g of a 30% hydrogen peroxide solution was added at room temperature, and the reaction solution was stirred at 20 to 30°C for 3 days. The reaction solution was concentrated under reduced pressure to obtain 2.6 g of a compound 7.  $^{13}\text{C}$ -NMR ( $\text{D}_2\text{O}$ )  $\delta$  178.6, 129.5, 75.7.

##### **[0048]** Synthesis Example 2 (Preparation of compound 8)

5.0 g of croconic acid was dissolved in 50 ml of pure water. To the solution, 2.0 g of a 30% hydrogen peroxide solution was added at room temperature, and the reaction solution was stirred at 100°C for 24 hours. The reaction solution was concentrated under reduced pressure to obtain 3.3 g of a compound 8.  $^{13}\text{C}$ -NMR ( $\text{D}_2\text{O}$ )  $\delta$  195.3, 193.9, 180.5, 178.7, 176.7, 161.7, 151.3, 150.0, 129.7, 75.8, 73.1, 72.5, 59.9, 45.9, 39.8.

#### (Compound screening)

##### 1. Preparation of biotinylated siRNA

**[0049]** Single-stranded RNA (sense strand: SEQ ID NO: 1) consisting of 21 bases was prepared, and this sequence was 3'-terminally biotinylated. Next, single-stranded RNA (antisense strand: SEQ ID NO: 2) consisting of 21 bases complementary to this sense strand was annealed thereto. This annealing product was purified to prepare biotinylated siRNA of 21 base pairs.

##### 2 Preparation of PTGS-SP

###### 1) Preparation of TBSV-p19

**[0050]** The PTGS-SP p19 (Genbank Accession No. NC\_001554) of TBSV used in screening was expressed and purified as follows: constructs comprising a p19 gene and a flag-tag sequence ligated to a vector pCold I DNA (TAKARA

BIO INC.) for cold shock expression were prepared, and *E. coli* BL21 strains were transformed with the constructs. The strains were cultured at 15°C for 24 hours in the presence of 0.1 mM IPTG to induce the expression. The strains were collected and homogenized. After centrifugation, the supernatant was subjected to extraction using a vector-derived His-tag and an Ni-NTA column with 200 mM to 500 mM imidazole. The expressed p19 was confirmed using anti-flag antibodies. The p19 in the extraction fraction was purified.

## 2) Preparation of TAV-2b

**[0051]** The 2b (Genbank Accession No. NC\_003838) of TAV used in screening was expressed and purified as follows: constructs pMAL-TAV2b-flag comprising a TAV-2b gene and a flag-tag sequence ligated to a vector pMAL-c2X (BioLabs Inc.) were prepared, and *E. coli* strains JM109 were transformed with the constructs and cultured in an LB/Amp medium at 37°C. The expression was induced for 2 hours in the presence of 0.3 mM IPTG. After centrifugation, the strains were washed and resuspended in a buffer solution. These strains were homogenized using a homogenizer. After centrifugation, the supernatant fraction was applied to an amylose-lysine column, and elution with 10 mM maltose was performed to obtain MBP-fused TAV-2b. The expressed MBP-TAV2b-flag was confirmed by SDS-PAGE and then cleaved using Factor Xa to separate between MBP and TAV2b-flag. The TAV2b-flag fraction was obtained by purification using a flag column.

## 3) Preparation of synthetic peptide

**[0052]** A peptide (SEQ ID NO: 3) comprising the portion of a few consecutive or adjacent strongly basic amino acids (arginines) contained in HIV tat was designed as a synthetic peptide having a partial structure of the PTGS-SP based on the sequence information of the PTGS-SP. The actual synthesis was conducted by a contract manufacturer of peptide synthesis (Biologica Co., Ltd.) to obtain a peptide having 98% purity.

## 3 Screening

### 1) Surface plasmon resonance method










**[0053]** An apparatus Biacore X (manufactured by Biacore) was used. A solution of the 3'-terminally biotinylated siRNA (10 µg/ml) of 21 base pairs was injected at a rate of 5 µl/min to a sensor chip SA modified with streptavidin to immobilize the siRNA on the sensor chip. A test compound used in screening was dissolved in dimethylformamide (DMF) or water such that it was adjusted to 25 ppm in terms of the final compound concentration. The PTGS-SP p19 or TAV-2b was dissolved in a buffer solution for Biacore (0.01 M HEPES, pH 7.4, 0.15 M NaCl, 3 mM EDTA) such that it was adjusted to approximately 10 µg/ml in terms of the final concentration. The test compound was mixed with the PTGS-SP. After centrifugation, bovine serum albumin was added to the supernatant, and the mixture was dialyzed at 4°C for 2 hours using a dialysis membrane (manufactured by PIERCE, 7000MWCO) and then adjusted to the concentrations described above to obtain a sample solution of the test compound. The Biacore X apparatus was operated according to the manual to measure the influence of the test compound on the binding of the siRNA immobilized on the sensor chip to the PTGS-SP. The binding inhibition rate of the test compound was calculated with non-biotinylated free siRNA (final concentration: 0.1 µM) as a positive control when an inhibition rate obtained without the compound addition is defined as 0% and an inhibition rate obtained using the positive control is defined as 100%. The binding inhibitory activity of the compound of the present invention on the p19 or TAV-2b is shown in Table 2.

### 2) Gel shift assay method

**[0054]** A test compound used in screening was dissolved in dimethylformamide (DMF) or water such that it was adjusted to 100 ppm in terms of the final compound concentration. A gel shift assay kit (LightShift Chemiluminescent EMSA Kit manufactured by Pierce) was used. The synthetic peptide of tat (500 nM) and the test compound solution were mixed into a buffer solution supplemented with 0.005% BSA, and the mixture was shaken at 25°C for 30 minutes. Then, the biotinylated siRNA (500 pM) was mixed therewith, and the mixture was further shaken at 25°C for 30 minutes. Each sample was electrophoresed on a 5% polyacrylamide gel and then transferred to a nylon membrane for 1 hour. The membrane was blocked and then treated with peroxidase-conjugated streptavidin. A luminol-peroxide substrate solution was added thereto for reaction, and the membrane was covered with an X-ray film and exposed to light for approximately 2 minutes. The binding inhibition rate of the test compound was calculated from the band positions and concentrations of the electrophoresed free biotinylated siRNA or the electrophoresed biotinylated siRNA bound with the synthetic peptide. The binding inhibitory activity of the compound of the present invention on the synthetic peptide of tat is shown in Table 2.










[0055]

[Table 2]

Compound No.	Structural formula	Binding inhibition rate (%)		
		Biacore		Gel shift
		p19 25 ppm	TAV2b 25 ppm	tat 100 ppm
1		80	80	10
2		75	0	-
3		0	90	-
4		20	90	-
5		100	100	100
6		100	100	100
7	Compound of Synthesis Example 1	100	100	100
8	Compound of Synthesis Example 2	100	100	100
9		95	0	0
10		70	50	-
11		70	20	-

# EP 2 127 675 A1

(continued)

Compound No.	Structural formula	p19 25 ppm	TAV2b 25 ppm	tat 100 ppm
12		100	95	100
13		-	-	100
14		-	-	100
15		95	100	80
16		80	0	0
17		100	90	-
18		90	80	0
19		90	50	0
20		100	80	100

## 3) Protoplast method

**[0056]** The leaf abaxial epidermis of tobacco (*Nicotiana benthamiana*) seedlings was stripped off and left standing at 25°C for approximately 6 hours in an enzyme solution (2% cellulase RS, 0.5% macerozyme R10, 0.5 M mannitol). This solution was subjected to filtration through two-piece gauze, and mannitol (0.4 M) addition and centrifugation (300 rpm,

2 min) were repeated three times to obtain protoplast. This protoplast was transfected by a PEG method with the following four nucleic acids: an expression plasmid for firefly luciferase (Fluc) as a reporter gene, an expression plasmid for *Renilla* luciferase (Rluc) as an internal standard, dsRNA of firefly luciferase (Fluc) for inducing silencing, and a PTGS-SP CMV 2b gene. The protoplast was cultured for approximately 24 hours and then homogenized. The expression level of each

Fluc or Rluc protein intracellularly expressed was measured as light emission. A test compound was added at the predetermined concentration before the culture, and its inhibitory activity was determined based on the Fluc/Rluc ratio in the presence or absence of the compound.

The inhibitory activity of the compound 7 of the present invention on the CMV-2b is shown in Figure 1. The ordinate represents the emission intensity of the firefly luciferase reporter gene. The emission intensity was decreased in a manner dependent on the concentration of the compound 7.

#### 4) Silencing plant method

**[0057]** A petunia variety was used whose pigment gene expression was inhibited by natural PTGS such that the flower had a white star pattern. This petunia was inoculated and infected with a CMV-L line to prepare a virus disease-affected petunia with completely inhibited natural PTGS, which was then used as a test plant for the PTGS-SP function. To eliminate individual difference, the number of the disease-affected petunia was increased by cuttings, which were then used in the inhibition test. A test compound used in screening was dissolved in dimethylformamide (DMF) or water and adjusted with an MES buffer solution to pH of 5.5 to 6.0 (final concentration: 100 to 1000 ppm). The solution of the compound of the present invention was injected into soil around the test plant, and a change in the flower color of the petunia starting to flower after 1 to 2 weeks was observed to determine the inhibitory activity of the compound on the PTGS-SP function, based on the recovery of the white star pattern.

The inhibitory activity of the compound 7 of the present invention on the CMV-2b is shown in Figure 2.

The CMV-infected petunia flower (upper box of Figure 2) had no detectable white star pattern, whereas the flower underwent the injection of the compound 7 of the present invention into soil (middle box of Figure 2) recovered a white star pattern as in a healthy flower (lower box of Figure 2).

#### 5) Symptom test method

**[0058]** A compound solution diluted to the predetermined concentration was gently injected with a syringe into the abaxial leaf epidermis of tobacco (*Nicotiana benthamiana*) seedlings. A dry leaf infected with a virus (TAV) was ground with a 10-fold volume of a 0.1 M phosphate buffer solution (pH 7.0) to prepare a crude sap, which was then used as an inoculation sap and wound-applied using Carborundum to the surface of the tobacco leaf to which the compound was injected. After the inoculation, the symptom of the viral disease was observed to determine the antiviral activity of the compound.

The antiviral activity of the compound 7 of the present invention is shown in Figure 3. The progression of the symptom in the tobacco treated with the compound 7 of the present invention was slower than that in untreated tobacco, demonstrating the inhibition of pathogenesis.

#### Industrial Applicability

**[0059]** A PTGS-SP binding inhibitor of the present invention can inhibit the binding of PTGS-SP produced by a virus to a substance  $\alpha$  such that the PTGS-SP function is decreased, wherein the substance  $\alpha$  has the property of inducing PTGS and the property of binding to the PTGS-SP and shows a decrease in the property of inducing PTGS upon binding to the PTGS-SP. The PTGS-SP binding inhibitor of the present invention can decrease the PTGS inhibitory effect involving the PTGS-SP and thereby restore the original action of PTGS, resulting in the inhibited growth or reduced toxicity of the virus that has infected organisms. Therefore, the PTGS-SP binding inhibitor of the present invention can be used as an antiviral agent. The antiviral agent of the present invention has a different mechanism of action from that of known antiviral agents and is therefore expected to be sufficiently effective for, for example, viruses resistant to known antiviral agents.

**[0060]** Moreover, the antiviral agent of the present invention inhibits the binding of PTGS-SP to siRNA such that the PTGS-SP function is inhibited. The antiviral agent of the present invention acts on the functions of PTGS-SPs carried in common by many pathogenic viruses and is therefore expected to be effective for a wider range of viruses. Specifically, X-ray crystallography or the like has revealed that many PTGS-SPs bind, at a site called a nucleic acid-binding region, to siRNA (Non-Patent Document 5). It was demonstrated that the PTGS-SPs bind thereto particularly at a site where two or more strongly basic amino acids (arginines or lysines) are consecutive or adjacent in a primary sequence or three-dimensional positional relationship. The presence of the site of PTGS-SP having such strongly basic amino acids with a high frequency is the condition necessary to bind to siRNA and is a common characteristic of the PTGS-SPs



carried by pathogenic viruses. Therefore, the antiviral agent of the present invention is expected to be effective for a wide range of viruses.

**[0061]** The antiviral agent of the present invention, when used in animals, produces therapeutic effects on viral diseases caused by pathogenic viruses. Further, the antiviral agent of the present invention, when used in plants, can reduce severe damage caused by viral diseases and significantly improve the commercial value and productivity of crops.

5

10

15

20

25

30

35

40

45

50

55

5

## SEQUENCE LISTING

&lt;110&gt; Nippon Soda CO.,Ltd.

10

&lt;120&gt; antiviral agent

&lt;130&gt; CASE784

15

&lt;160&gt; 3

20

&lt;170&gt; PatentIn version 3.4

&lt;210&gt; 1

&lt;211&gt; 21

25

&lt;212&gt; RNA

&lt;213&gt; Artificial

30

&lt;220&gt;

&lt;223&gt; ssRNA-sense

35

&lt;400&gt; 1

uugcucaaca guaugggcau u

21

40

&lt;210&gt; 2

&lt;211&gt; 21

&lt;212&gt; RNA

&lt;213&gt; Artificial

45

&lt;220&gt;

&lt;223&gt; ssRNA-antisense

50

&lt;400&gt; 2

ugcccauacu guugagcau u

21

55

<210> 3

<211> 34

<212> PRT

<213> Artificial

<220>

<223> designed peptide based on amino acid sequence in dsRNA binding motif of tat

<400> 3

Arg Lys Lys Arg Arg Gln Arg Arg Arg Pro Pro Gln Gly Ser Gln Thr

1 5 10 15


His Gln Val Ser Leu Ser Lys Gln Pro Thr Ser Gln Ser Arg Gly Asp

20 25 30


Pro Thr

#### Claims


1. A PTGS suppressor protein binding inhibitor containing a compound having inhibitory activity on the binding of a substance  $\alpha$  to a PTGS suppressor protein, wherein the substance  $\alpha$  has a property of inducing PTGS and a property of binding to the PTGS suppressor protein and shows a decrease in the property of inducing PTGS upon binding to the PTGS suppressor protein.
2. The PTGS suppressor protein binding inhibitor according to claim 1, wherein the substance  $\alpha$  is siRNA.
3. The PTGS suppressor protein binding inhibitor according to claim 1 or 2, wherein the compound is at least one selected from the group consisting of cyclic ketone compounds represented by the following formulas (1) to (6):




.... Formula (1)




.... Formula (2)




.... Formula (3)



.... Formula (4)




.... Formula (5)




.... Formula (6)


4. The PTGS suppressor protein binding inhibitor according to claim 1 or 2, wherein the compound is a reaction product of croconic acid with hydrogen peroxide.
5. An antiviral agent comprising, as an active ingredient, a compound having inhibitory activity on the binding of a substance  $\alpha$  to a PTGS suppressor protein, wherein the substance  $\alpha$  has a property of inducing PTGS and a property of binding to the PTGS suppressor protein and shows a decrease in the property of inducing PTGS upon binding to the PTGS suppressor protein.
6. The antiviral agent according to claim 5, wherein the substance  $\alpha$  is siRNA.
7. The antiviral agent according to claim 5 or 6, wherein the compound is at least one selected from the group consisting of cyclic ketone compounds represented by the following formulas (1) to (6):




.... Formula (1)




.... Formula (2)




.... Formula (3)



.... Formula (4)



.... Formula (5)



.... Formula (6)

8. The antiviral agent according to claim 5 or 6, wherein the compound is a reaction product of croconic acid with hydrogen peroxide.

Figure 1







Figure 2



CMV-infected




Effect of compound 7  
of the present invention



Healthy



Figure 3



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2008/000655

## A. CLASSIFICATION OF SUBJECT MATTER

A61K45/06(2006.01)i, A61K31/122(2006.01)i, A61K31/7105(2006.01)i,  
A61K48/00(2006.01)i, A61P31/12(2006.01)i, A61P31/16(2006.01)i, A61P43/00  
(2006.01)i

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K45/06, A61K31/122, A61K31/7105, A61K48/00, A61P31/12, A61P31/16,  
A61P43/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Jitsuyo Shinan Koho 1922-1996 Jitsuyo Shinan Toroku Koho 1996-2008  
Kokai Jitsuyo Shinan Koho 1971-2008 Toroku Jitsuyo Shinan Koho 1994-2008

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

BIOSIS/CaPlus/EMBASE/MEDLINE/REGISTRY(STN), JSTPlus/JMEDPlus/JST7580  
(JDreamII), Igaku·Yakugaku Yokoshu Zenbun Database

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y A	SAGAN, S.M. et al., Inhibition of siRNA Binding to a p19 Viral Suppressor of RNA Silencing by Cysteine Alkylation, Angewandte Chemie International Edition, 2007.03.12, Vol.46, No.12, pp.2005-2009 page 2005, left column, line 1 to right column, line 2; page 2006, right column, 3rd paragraph; Fig. 3	1, 2 5, 6 3, 4, 7, 8
X A	MATSUMOTO, M. et al., Selective nonpeptidic inhibitors of herpes simplex virus type 1 and human cytomegalovirus proteases, Biological & Pharmaceutical Bulletin, 2001, Vol.24, No.3, pp.236-241, Abstract, Table 1, Compound No.4	1-3, 5-7 4, 8

☒ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search  
11 April, 2008 (11.04.08)

Date of mailing of the international search report  
22 April, 2008 (22.04.08)

Name and mailing address of the ISA/  
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2008/000655

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y A	LAKATOS, L. et al., Small RNA binding is a common strategy to suppress RNA silencing by several viral suppressors, The EMBO Journal, 2006, Vol.25, pp.2768-2780, Abstract	5,6 4,8
P,X	KOUKIEKOLO, R. et al., Effects of pH and salt concentration on the siRNA binding activity of the RNA silencing suppressor protein p19, FEBS Letters, 2007.06, Vol.581, pp.3051-3056 Abstract, Results	1,2,5,6
A	JP 2004-344110 A (Japan Science and Technology Agency), 09 December, 2004 (09.12.04), (Family: none)	1-8

Form PCT/ISA/210 (continuation of second sheet) (April 2007)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2008/000655

## &lt;Subject of search&gt;

Claims 1, 2, 5 and 6 involve use of various compounds, which are defined by the desired property "having an activity of inhibiting the binding of substance  $\alpha$ , which has a property of inducing PTGS and a property of binding to a PTGS suppressor protein and shows a decrease in the property of inducing PTGS in the state of binding to the PTGS suppressor protein, to the PTGS suppressor protein" as a PTGS suppressor protein-binding inhibitor or an antiviral agent. However, nothing but the case of using the compounds specified in Table 1 in the description, from among the claimed compounds, is supported by the description in the meaning within PCT Article 6 and disclosed therein in the meaning within PCT Article 5.

Although the common technical knowledge at the point of the application is taken into consideration, such substances as defined by the desired property "substance  $\alpha$  having a property of inducing PTGS and a property of binding to a PTGS suppressor protein and showing a decrease in the property of inducing PTGS in the state of binding to the PTGS suppressor protein" or "a compound having an activity of inhibiting the binding of substance  $\alpha$  to a PTGS suppressor protein" cannot be specified. Therefore, claims 1, 2, 5 and 6 do not comply with the requirement of clearness as defined in PCT Article 6 too.

In the present international search report, therefore, the results of the search on prior art relating to the binding of siRNA/dsRNA to a PTGS suppressor protein and to the relationship between the compounds specified in Table 1 and the PTGS/antiviral activity are presented.

On the other hand, a complete search was made on claims 3, 4, 7 and 8.

## REFERENCES CITED IN THE DESCRIPTION

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

### Patent documents cited in the description

- JP 2004344110 A [0011]

### Non-patent literature cited in the description

- **Goto K. et al.** *Plant Cell Physiol.*, 2007, vol. 48, 1050-60 [0011]
- **Anandalakshmi R. et al.** *Proc. Natl. Acad. Sci. USA*, 1998, vol. 95, 13079-13084 [0011]
- **Brigneti G. et al.** *EMBO J.*, 1998, vol. 17, 6739-6746 [0011]
- **Voinnet O. et al.** *Cell*, 2000, vol. 103, 157-167 [0011]
- **Baulcombe DC. et al.** *Trends Biochem Sci.*, 2004, vol. 29, 279-81 [0011]
- **Qu F. et al.** *J. Virol.*, 2003, vol. 77, 511-522 [0011]